On the whole, the historical undruggable KRAS alteration is likely to be targeted and a significant turning point has been reached, allowing to offer a range of opportunities in the growing individualized treatment paradigm for KRAS-mutant NSCLC patients (Figure 1). Here, KRAS is linked to non-small cell lung carcinoma.